Tokio Marine Asset Management Co. Ltd. Buys 107 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,048 shares of the company’s stock after acquiring an additional 107 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $402,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Lindbrook Capital LLC increased its stake in Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after acquiring an additional 96 shares during the last quarter. Headinvest LLC bought a new stake in Neurocrine Biosciences during the third quarter worth approximately $28,000. BluePath Capital Management LLC bought a new stake in Neurocrine Biosciences during the third quarter worth approximately $35,000. Sunbelt Securities Inc. increased its stake in Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after acquiring an additional 83 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Neurocrine Biosciences by 51.3% during the third quarter. Fifth Third Bancorp now owns 622 shares of the company’s stock valued at $70,000 after buying an additional 211 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

NBIX has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 24th. Barclays upped their target price on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Citigroup cut their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a research note on Thursday, February 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $147.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Neurocrine Biosciences Trading Down 1.3 %

Shares of NBIX opened at $135.99 on Monday. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37. The stock has a fifty day moving average price of $136.63 and a 200-day moving average price of $128.04. The firm has a market cap of $13.53 billion, a PE ratio of 56.19 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. During the same quarter in the prior year, the business posted $0.88 EPS. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. As a group, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.8 EPS for the current year.

Insider Activity

In related news, insider Ingrid Delaet sold 200 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $140.00, for a total value of $28,000.00. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,050,980. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Ingrid Delaet sold 200 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $140.00, for a total value of $28,000.00. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,050,980. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eiry Roberts sold 1,457 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total value of $205,131.03. Following the completion of the transaction, the insider now directly owns 20,832 shares in the company, valued at $2,932,937.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 186,994 shares of company stock worth $25,806,409. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.